PlainRecalls
FDA Drug Critical Class I Ongoing

Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC# 31722-629-21.

Reported: May 17, 2023 Initiated: March 13, 2023 #D-0567-2023

Product Description

Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC# 31722-629-21.

Reason for Recall

Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.

Details

Units Affected
1568 bottles
Distribution
Nationwide in the USA
Location
Piscataway, NJ

Frequently Asked Questions

What product was recalled?
Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC# 31722-629-21.. Recalled by Camber Pharmaceuticals Inc.. Units affected: 1568 bottles.
Why was this product recalled?
Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 17, 2023. Severity: Critical. Recall number: D-0567-2023.